Bridging gaps in diabetic neuropathy care: A Delphi\u2010based regional consensus from the Gulf Cooperation Council

Association of BCAAs/BCKAs with pancreatic steatosis in patients with type 2 diabetes mellitus: A cross\u2010sectional study

Effects of esaxerenone add\u2010on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Serum\u2010derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis

Real-world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium-glucose cotransporter-2 inhibitor therapy.

Bridging gaps in diabetic neuropathy care: A Delphi\u2010based regional consensus from the Gulf Cooperation Council

Association of BCAAs/BCKAs with pancreatic steatosis in patients with type 2 diabetes mellitus: A cross\u2010sectional study

Effects of esaxerenone add\u2010on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Serum\u2010derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis

Real-world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium-glucose cotransporter-2 inhibitor therapy.